Breast Cancer Clinical Trial
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
Summary
This is a live biobank study for Triple negative breast cancer (TNBC) patients where samples will be collected at inflection points in the course of the disease.
Full Description
To test this hypothesis the investigators will focus on studying TNBC patients using an innovative approach, the DIGNITY Study (De-convoluting interactions between genes, the cancer environment, and the immune system to develop therapies that work for you) designed to building a live tissue biobank of Patient Derived Tumor Organoids (PDOs) derived from tumor at surgery, preceded or not by neoadjuvant therapy (NAT), and at recurrence/metastasis. TNBC patients enrolled in this study are consented to enable investigators to generate a biobank of tumor tissue (obtained from surgically removed excess that would otherwise be disposed off ) and matched blood cells ( obtained from an already existing line or a venipuncture ordered per standard of care testing) at key timepoints in their treatment course.
Eligibility Criteria
Inclusion Criteria:
All patients will historically proven TNBC are eligible to be on the study
Exclusion Criteria:
Carriers of other breast cancers than TNBC.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
New York New York, 11215, United States More Info
Principal Investigator
New York New York, 11355, United States More Info
Sub-Investigator
Principal Investigator
How clear is this clinincal trial information?
